ArticleFrontiers in immunology2025
Concomitant medication use and clinical outcome in hepatocellular carcinoma treated with immune-based therapy: a multicenter analysis.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prediction of Response to Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?Cancers · 2026Review
- Antibiotic exposure and indication-specific corticosteroid use differentially modulate outcomes of immune checkpoint inhibitor therapy in hepatobiliary malignancies.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Immune checkpoint inhibitors (ICIs) have been increasingly used in hepatocellular carcinoma (HCC). Despite emerging evidence indicating that concomitant medications might impact clinical outcomes, their association with ICI efficacy is undefined in HCC. Methods: The multicenter cohort included 851 HCC patients receiving ICIs between January 2018 and December 2022 in 13 institutions. Concomitant medications given within 30 days before or after the initiation of ICIs were evaluated in association with survival, tumor response, and treatment-related adverse event (TRAE) occurrence. Concomitant medications administered within 30 days before or after the initiation of ICI therapy were identified and used to categorize patients into user and non-user groups for each medication class. The primary outcomes were overall survival (OS), and secondary outcomes included progression-free survival (PFS), time to progression (TTP), tumor response, and TRAEs. Tumor response was evaluated based on RECIST 1.1. Multivariable Cox and logistic regression models were used to adjust for confounding variables. Results: The median OS (13.6 vs. 20.7 months; P = 0.006) and PFS (6.6 vs. 8.9 months; P = 0.002) were significantly reduced for antibiotic users compared to non-users, while other drugs did not show an impact on patient outcomes. In multivariable analysis, antibiotic use predicted worse survival outcomes (OS: HR = 1.88, 95% CI, 1.14-3.11; P = 0.014; PFS: HR = 1.60, 95% CI, 1.20-2.13; P = 0.001). Patients who underwent glucocorticoids for early TRAE management achieved longer OS than those for prophylactic use (OS: Not reached vs. 20.3 months; HR = 0.25, 95% CI, 0.10-0.65; P = 0.042). Concomitant use of medications such as antibiotics, H2RAs, and glucocorticoids was associated with increased incidence of specific TRAEs, particularly involving hematologic, hepatic, and endocrine systems. Conclusion: This study identified antibiotic use as a negative prognostic factor in HCC treated with ICIs, while glucocorticoid for early TRAEs may indicate improved survival benefits. Concomitant medication may affect the occurrence of TRAEs and warrants careful consideration during ICI treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.